CASE REPORT
Myeloma-related disorder with leukaemic progression in a cat

Yoshinori Takeuchi DVM1, Haruna Iizuka DVM1, Hiroyuki Kanemitsu MS, PhD2, Yasuhiro Fujino DVM, PhD1, Ko Nakashima DVM1, Kazuyuki Uchida DVM, PhD, Dip JCVP2, Koichi Ohno DVM, PhD1, Hiroyuki Nakayama DVM, PhD, Dip JCVP2, Hajime Tsujimoto DVM, PhD1*

1Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
2Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan

A 10-year-old American Shorthair cat with nasal discharge, anorexia, and weight loss was found to have pancytopenia and hyperproteinaemia. Bone marrow aspiration revealed atypical plasma cells that totalled 50% of the nucleated bone marrow cells. The number of atypical plasma cells progressively increased in the peripheral blood during the observation period of 64 days. The cat did not respond to treatments with melphalan, chlorambucil, and prednisolone, and died 71 days after the initial presentation. Clinical, cytological, histopathological, and immunohistochemical findings in this case supported the diagnosis of myeloma-related disorder (MRD) with leukaemic progression.

Historical diagnostic criteria for multiple myeloma (MM) in veterinary medicine require at least two of the following: paraproteinaemia/monoclonal gammopathy, radiographic evidence of osteolytic bone lesions, Bence-Jones proteinuria, and increase in the number of neoplastic plasma cells to more than 5% of the nucleated bone marrow cells.1,2 However, MM and advanced extramedullary plasmacytoma cannot always be distinguished by these criteria; therefore, the diagnostic criteria for MM in cats remain controversial.3 Recently, Mellor et al proposed an all-encompassing term ‘myeloma-related disorders (MRD)’ for neoplasms of plasma cell origin in cats, and indicated that cats with MRD commonly had extramedullary involvement at the initial clinical presentation3 while human patients with the MM did not.7,8 In the present report, we describe a feline case of MRD showing a progressive increase in the number of atypical plasma cells in the peripheral blood.

A 10-year-old neutered male American Shorthair cat was referred to the Veterinary Medical Center of the University of Tokyo with a 2-week history of nasal discharge, anorexia, and weight loss. On physical examination, the body weight was 6.4 kg (body condition score: 2/5), and visible mucous membranes were slightly pale. A complete blood cell count measured with a multiple automated haematology analyser (pocH-100iV diff; Sysmex, Hyogo, Japan) revealed non-regenerative anaemia and thrombocytopenia (Table 1). On a peripheral blood smear, plasmacytosis (2% of blood leukocytes) and mild rouleaux were noted. The blood chemical profile measured with an automated biochemical analyser (Dri-Chem 7000 V; FUJIFILM, Tokyo, Japan) indicated hyperproteinaemia, increases in alanine aminotransaminase and alkaline phosphatase activity, and increased blood urea nitrogen (Table 1). Serum free T4 level measured by an automatic immunoassay analyser (IMX system; Abbott Diagnostics, North Chicago, IL) was below the reference interval at 0.88 ng/dl; (reference interval1–2.5 ng/dl) which supports the effects of other illness on thyroid levels. Tests for feline leukaemia virus antigen and feline immunodeficiency virus antibody were both negative (Snap FelV/FIV Combo Test: Idexx, Westbrook, ME). A test for serum antibody directed to feline coronavirus was also negative (Marupi Lifetec, Osaka, Japan).

Thoracic and abdominal radiographs revealed cardiomegaly, hepatomegaly, and splenomegaly.
Echocardiography revealed thickening of the interventricular septum and left ventricular free wall and dilatation of the left atrium. Radiographic examinations of extremities, vertebrae and costae revealed no osteolytic lesions. Abdominal ultrasonography demonstrated a mixed echoic mass with a diameter of 2.5 cm in the spleen as well as an ascites and dilated hepatic veins.

On day 17, atypical plasma cells, which contained a round or pleomorphic nucleus, moderately basophilic cytoplasm, and poorly defined perinuclear Golgi zones, were observed in the peripheral blood smear, accounting for 32% of the blood leukocytes (Fig 1A and Table 1). In order to stabilise the patient before general anaesthesia and bone marrow aspiration, a whole blood transfusion was carried out on days 17 and 18.

Table 1. Haematological values and blood chemistry profiles.

| Blood examination                  | Day 1 | Day 17 | Day 29 | Day 36 | Day 52 | Day 64 | Reference ranges* |
|------------------------------------|-------|--------|--------|--------|--------|--------|-------------------|
| Red blood cells (x10^6/μl)         | 3.92  | 5.76   | 4.82   | 4.20   | 5.77   | 3.67   | NA                |
| Haemoglobin (g/dl)                 | 5.1   | 7.6    | 6.4    | 5.8    | 8.3    | 5.3    | 8.0–15.0          |
| Packed cell volume (%)             | 17.0  | 23.0   | 18.0   | 17.0   | 23.0   | 17.0   | 30.0–45.0         |
| White blood cells (μl)             | 3600  | 2300   | 2400   | 3800   | 6400   | 7800   | 5000–19,000       |
| Neutrophils, band (μl)             | 0     | 40     | 140    | 190    | NT     | 470    | 0–300             |
| Neutrophils, segmented (μl)        | 2060  | 1310   | 1370   | 1630   | NT     | 3,820  | 2000–12,000       |
| Lymphocytes (μl)                   | 1110  | 140    | 190    | 490    | NT     | 80     | 1000–7000         |
| Monocytes (μl)                     | 220   | 0      | 50     | 110    | NT     | 390    | 0–1000            |
| Eosinophils (μl)                   | 140   | 70     | 50     | 0      | NT     | 0      | 0–1000            |
| Basophils (μl)                     | 0     | 0      | 0      | 0      | NT     | 0      | NA                |
| Atypical plasma cells (μl)         | 70    | 740    | 580    | 1330   | NT     | 2,340  | NA                |
| Atypical plasma cells (%)          | 2     | 32     | 24     | 35     | NT     | 30     | NA                |
| Platelets (x10^3/μl)               | 11    | 81     | 25     | 13     | 34     | 11     | 200–700           |
| Blood urea nitrogen (mg/dl)        | 37.8  | NT     | NT     | NT     | 284.5  | 169.0  | 10.0–30.0         |
| Creatinine (mg/dl)                 | 1.6   | NT     | NT     | NT     | 9.9    | 7.4    | 0.8–2.0           |
| Alkaline phosphatase (U/l)         | 381   | NT     | NT     | NT     | NT     | 356    | <200              |
| Alanine aminotransferase (U/l)     | 247   | NT     | NT     | NT     | NT     | 37     | <80               |
| Total protein (g/dl)               | 10.8  | 10.8   | 8.4    | 8.2    | 9.8    | 8.0    | 5.5–7.9           |
| Albumin (g/dl)                     | 3.5   | NT     | 3.2    | NT     | 3.5    | NT     | 2.1–3.4           |
| Ca (mg/dl)                         | 11.4  | NT     | NT     | 8.2    | NT     | 8.0    | 8.0–12.0          |

NT = not tested. NA = not available.

*The reference ranges were based on ‘Hematology’ by Susan M Cotter for haematologic values and ‘Laboratory profiles of small animal diseases, 3rd edn’ for blood chemistry profiles.

On day 18, the cat was initially treated with prednisolone (Predonine; Shionogi, 0.8 mg/kg, PO, q12 h) and furosemide (Lasix; Sanofi-Aventis, 0.7 mg/kg, PO, q12 h) in addition to intravenous whole blood transfusions (40–60 ml) four times until day 16.

On day 21, although the number of circulating plasma cells slightly decreased, there was a progression of pancytopenia; therefore, melphalan was discontinued. Thereafter, the cat was treated with prednisolone and recombinant human granulocyte-colony stimulating factor (Neutrogin; Chugai Pharmaceutical, 5 μg/kg, SC, on days 29 and 38) in addition to the intermittent whole blood transfusions (40–45 ml, nine times, from day 36 to day 65). An increase in the atypical plasma cells in the peripheral blood (1330/μl, 35% of blood leukocytes) (Table 1) was observed on day 36. On day 38, atypical plasma cells with villous cytoplasmic projections were observed in the peripheral blood (Fig 1B). On day 52, elevated blood urea nitrogen (284.5 mg/dl) and creatinine (9.9 mg/dl) concentrations were found, and the cat showed appendicular oedema. Chemotherapy with chlorambucil (Leukeran; GlaxoSmithKline, 3 mg/m², PO, q24 h) was started from day 58; however, an increase of large-sized atypical plasma cells was noted in the peripheral blood on
Fig 1. Cytological findings of the peripheral blood and bone marrow. (A) Peripheral blood smear on day 17: two atypical plasma cells are shown. (B) Peripheral blood smear on day 38: several plasma cells with villous cytoplasmic projections are observed (arrow). (C, D) Bone marrow smear on day 18: proliferation of atypical plasma cells. A–D: Wright–Giemsa stain. Bars = 10 μm (A, B, D), 50 μm (C).

Table 2. Myelograms.

| Bone marrow cells                  | Day 18   | Day 71   | Reference ranges* |
|------------------------------------|----------|----------|-------------------|
| Proerythroblasts                   | 0.4%     | 0%       | 1.00 ± 0.54%      |
| Basophilic erythroblasts           | 1.4%     | 0.4%     | 4.02 ± 1.56%      |
| Polychromatic erythroblasts        | 8.0%     | 14.7%    | 17.57 ± 4.48%     |
| Orthochromatic erythroblasts       | 14.6%    | 1.2%     | 5.54 ± 3.15%      |
| Myeloblasts                        | 0.2%     | 0%       | 0.08 ± 0.16%      |
| Promyelocytes                      | 0.8%     | 0.4%     | 1.74 ± 1.04%      |
| Neutrophilic myelocytes            | 1.4%     | 1.6%     | 4.31 ± 2.49%      |
| Neutrophilic metamyelocytes        | 3.2%     | 0.4%     | 10.06 ± 3.20%     |
| Neutrophils, band                  | 6.8%     | 0.4%     | 14.40 ± 1.30%     |
| Neutrophils, segmented             | 10.0%    | 1.2%     | 12.86 ± 4.85%     |
| Eosinophils, band                  | 0.2%     | 0%       | 0.49 ± 0.40%      |
| Eosinophils, segmented             | 0.4%     | 0%       | 0.60 ± 0.20%      |
| Monocytes                          | 0.4%     | 0%       | 0.77 ± 0.51%      |
| Lymphocytes                        | 1.2%     | 0%       | 16.13 ± 2.92%     |
| Atypical plasma cells              | 50.4%    | 79.0%    | 0.80 ± 0.60%      |
| Megakaryocytes                     | 0.6%     | 0.4%     | NA                |
| Myeloid/erythroid ratio            | 0.94     | 0.27     | 1.63 ± 0.35       |

NA = not available.

*The reference ranges were based on ‘Schalm’s veterinary hematology, 5th edn’.11
day 64 (2340/μl, 30% of blood leukocytes) (Table 1). On day 66, in addition to the persistent thrombocytopenia, prolonged activated partial thromboplastin time (61.6 s, reference interval 21–45 s) and elevated concentration of fibrin/fibrinogen degradation product (5 μg/ml, reference interval <2.5 μg/ml) were noted, supporting the development of disseminated intravascular coagulation (DIC). The cat developed epistaxis and melena, and died 71 days after the initial presentation.

An autopsy revealed generalised subcutaneous oedema with pleural effusion and ascites (approximately 500 ml). The lung was diffusely congested and oedematous. The spleen and liver were diffusely enlarged, and there were multifocal haemorrhagic foci on their surfaces. There was no mass lesion in the spleen. Lymph nodes were grossly unremarkable. An impression smear of the bone marrow showed marked proliferation of atypical plasma cells (79% of all nucleated cells) and decreases in the number of the normal erythroid, myeloid, and megakaryocytic cells (Table 2). On the impression smear of the spleen, a large number of atypical plasma cells were also noted.

Histopathological examinations of the bone marrow revealed diffuse proliferation of medium- to large-sized plasma cells surrounded by the remnant haematopoietic cells (Fig 3A). The plasma cells were similar in appearance to those previously described, and the majority had marked anisocytosis, marked anisokaryosis, and bi- or multi-nucleation. Mitotic figures were rare. In the spleen, the normal structures were almost completely replaced by a diffuse proliferation of plasma cells, accompanied by minimal extra-medullary haematopoiesis (Fig 3B). The neoplastic foci were scattered throughout in the liver. The neoplastic plasma cells infiltrated into the hepatic central vein, sinusoid, and parenchyma, altering the normal architectures. The neoplastic plasma cells were also observed in the vessels of the visceral organs including heart, lung, kidney, intestine, pancreas, urinary bladder, and thyroid gland; however, there was no parenchymal infiltration of the neoplastic plasma cells in these organs. In both kidneys, glomerular mesangial cell proliferation and dilated medullary tubules containing proteinaceous casts were observed. The left ventricular wall of the heart was hypertrophic (thickness, 12 mm) and there was marked congestive oedema of the lung.

Immunohistochemistry for detection of IgG, IgM, IgA, and Ig light chain was performed in the bone marrow and kidney sections. To detect IgG, IgM and IgA, primary antibodies directed to feline IgG, IgM, and IgA (Bethyl Laboratories, Montgomery, TX), respectively, and labelled streptavidin biotinylated antibody method were employed. For detection of Ig light chain, a direct immunohistochemistry using horseradish peroxidase-conjugated anti-feline Ig light chain (κ and λ) (Bethyl Laboratories) was carried out. For the negative control, Tris-buffered saline was applied to the tissue sections instead of primary antibodies for immunohistochemistry. Most of the neoplastic cells in the bone marrow were negative for IgG, IgM, and IgA, but 5–10% of these neoplastic cells were positive for Ig light chain (Fig 3C). In the kidney, tubular casts and granules in the tubular epithelium were also positive for Ig light chain (Fig 3D).

Significant plasmacytosis in the peripheral blood is rare in feline MRD. In a report by Mellor et al, a small number of circulating plasma cells were observed in only 1/24 cats with MRD. In a case report by Rahakrishnan et al., there was progression from a cutaneous plasmacytoma to dissemination of neoplastic plasma cells in the marrow (73%) and peripheral blood with associated neutropenia and thrombocytopenia. This is in contrast to this case where anaemia, thrombocytopenia and atypical plasmacytosis were observed on initial presentation. The progressive marrow involvement by the proliferative plasma cells uncommonly results in leukaemia but likely contributes to the cytopenias.

Median survival time in cats with MRD has been variously reported at 284 days and at 6 months. The cat in this report did not respond to the combined chemotherapy regime and survived only 71 days. This is consistent with a previous case report where the cat succumbed within 3.5 months and was also treated with multiple combined chemotherapy regimes. The classification scheme by Mellor et al. defines a high proportion of plasmablasts as consistent with poorly differentiated MRD with short survival times (median 14 days). In the case described in this study, most of the neoplastic plasma cells corresponded to plasmablasts, therefore, the cat could be diagnosed with poorly differentiated MRD according to the categorisation system. Moreover, a feline case having MRD with significant plasmacytosis previously reported was treated with prednisolone, melphalan, doxorubicin,
L-asparaginase, and lomustine, but the cat was euthanased 3.5 months after confirming the leukaemic progression. Thereby, significant peripheral plasmacytosis may indicate a poor prognosis in feline MRD although studies on a large number of cases are warranted.

The changes of the echocardiography were consistent with those in hypertrophic cardiomyopathy; however, they might be associated with the long-term anaemia and blood hyperviscosity due to hyperglobulinaemia in the present cat. Appendicular oedema and pulmonary oedema detected during the observation period could be caused by the chronic heart failure.

Multiple blood transfusion, 14 in total, failed to maintain the PCV in this cat (Table 1). The replacement of marrow by the proliferating neoplastic population, blood loss due to the thrombocytopenia and reactions to the transfused blood elements may all have played a role in the persistent anaemia.

The present report details a case of feline MRD with leukaemic progression, appearing as a rare disease condition in cats. Further accumulation of the cases is needed in order to define its prognosis and therapeutic responses.

Fig 3. Histopathological findings of the bone marrow (A) and spleen (B) and immunohistochemical findings of the bone marrow (C) and kidney (D) obtained at autopsy. (A) Diffuse proliferation of neoplastic plasma cells surrounded by the cells of normal haematopoietic lineages is observed. (B) Normal splenic structures are substituted for the diffusely proliferated atypical plasma cells. (C) A proportion (5–10%) of the neoplastic cells are shown to be positive for Ig light chain in the cytoplasm. (D) Tubular casts and granules in tubular epithelia are shown to be positive for Ig light chain. A, B: Haematoxylin–eosin stain. C, D: Immunohistochemistry for feline Ig light chain (κ and λ), followed by methyl green counterstain. Bars = 25 μm (A, B), 50 μm (C, D).

Acknowledgments

This work was supported, in part, by grants from the Ministry of Education, Science, Sports, and Culture in Japan.

References

1. Hanna F. Multiple myelomas in cats. J Feline Med Surg 2005; 7: 275–87.
2. MacEwen EG, Hurvitz AI. Diagnosis and management of monoclonal gammopathies. Vet Clin North Am 1977; 7: 119–32.
3. Appel SL, Moens NM, Abrams-Ogg AC, Woods JP, Nykamp S, Bienzle D. Multiple myeloma with central nervous system involvement in a cat. J Am Vet Med Assoc 2008; 233: 743–7.
4. Patel RT, Caceres A, French AF, McManus PM. Multiple myeloma in 16 cats: a retrospective study. Vet Clin Pathol 2005; 34: 341–52.
5. Sheafor SE, Gamblin RM, Couto CG. Hypercalcemia in two cats with multiple myeloma. J Am Anim Hosp Assoc 1996; 32: 503–8.
6. Mellor PJ, Haugland S, Murphy S, et al. Myeloma-related disorders in cats commonly present as extramedullary neoplasms in contrast to myeloma in human patients: 24 cases with clinical follow-up. J Vet Intern Med 2006; 20: 1376–83.
7. Soutar R, Luraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma...
of bone and solitary extramedullary plasmacytoma. Br J Haematol 2004; 124: 717–26.
8. Kapadia SB. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore) 1980; 59: 380–92.
9. Shodikoff CH. Laboratory Profiles of Small Animal Diseases. 3rd edn. St Louis: Mosby, 2001.
10. Cotter SM. Hematology. Jackson: Teton Newmedia, 2001.
11. Clinkenbeard KD, Meinkoth JH. Normal hematology of the cat. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm’s veterinary hematology 5th edn. Oxford: Blackwell, 2000: 1064–8.
12. Mellor PJ, Haugland S, Smith KC, et al. Histopathologic, immunohistochemical, and cytologic analysis of feline myeloma-related disorders: further evidence for primary extramedullary development in the cat. Vet Pathol 2008; 45: 159–73.
13. Rahakrishnan A, Risbon RE, Patel RT, Ruiz B, Clifford CA. Progression of a solitary, malignant cutaneous plasma-cell tumour to multiple myeloma in a cat. Vet Comp Oncol 2004; 2: 36–42.
14. Bienzle D. Plasmacytoma and multiple myeloma. In: Valli VE, ed. Veterinary comparative hematopathology. Iowa: Blackwell, 2007: 189–206.